Oncogenic mutation drivers such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and repressor of silencing 1 (ROS-1) can alter the immune tumour microenvironment, which may induce anti-PD1/PD-L1 resistance. Here, PDCD1 is linked to neoplasm.